Mycept
Mycept (Mycophenolate Mofetil 250 mg) — Panacea Biotec selective IMPDH inhibitor for transplant rejection prevention and refractory autoimmune disease.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
Quick Answer
Mycept — Mycophenolate Mofetil 250 mg (Panacea Biotec). Selective inhibitor of inosine monophosphate dehydrogenase — for solid-organ transplant rejection prophylaxis (renal, cardiac, hepatic), refractory autoimmune disease (lupus nephritis, myasthenia gravis, vasculitis).
What you get with MedsBase:
- WHO-GMP certified manufacturer
- Discreet plain-envelope packaging
- Worldwide shipping
- Rated by 1,400+ customers (read reviews)
📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.
Why order from MedsBase
Mycept ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Immunosuppressants need ongoing specialist supervision (transplant, rheumatology, or haematology). Drug levels (cyclosporine, sirolimus, tacrolimus), FBC, LFTs, renal function, lipids, glucose, BP — all need regular monitoring. Infection surveillance is mandatory. Vaccination status must be optimised before starting; live vaccines contraindicated during therapy.
Long-term immunosuppression increases risks: opportunistic infections (PCP, CMV, EBV-driven PTLD), bacterial/fungal infection, reactivation of latent TB or HBV/HCV. Increased risk of skin cancer (especially squamous cell), lymphoproliferative disease, and other malignancies. Annual skin checks, regular cancer surveillance per guidelines.
Frequently Asked Questions
When is this used?
Selective inhibitor of inosine monophosphate dehydrogenase — for solid-organ transplant rejection prophylaxis (renal, cardiac, hepatic), refractory autoimmune disease (lupus nephritis, myasthenia gravis, vasculitis). Always specialist-supervised — transplant, rheumatology, haematology, or oncology context.
Why is monitoring needed?
Therapeutic drug monitoring (cyclosporine, sirolimus, tacrolimus): trough levels target organ-protection without toxicity. Renal function: most are nephrotoxic. Lipids/glucose: metabolic effects. FBC: marrow suppression.
Drug interactions?
Critical class — strong CYP3A4 substrates (calcineurin inhibitors, mTOR inhibitors). Many interactions: antifungals raise levels (often dramatically — even 5-10×), rifampicin drops levels (rejection risk), grapefruit raises levels. Any new medication should be checked first.
Vaccines?
Inactivated vaccines fine; live vaccines contraindicated during therapy. Optimise vaccinations BEFORE starting — pneumococcal, annual influenza, hepatitis B, varicella, MMR, HPV as appropriate.
Pregnancy?
Mycophenolate is teratogenic — strict contraception. Cyclosporine, tacrolimus, azathioprine are used in pregnancy with specialist supervision. mTOR inhibitors generally avoided. Always discuss family planning with specialist.
Cancer screening?
Skin checks every 6-12 months (lifelong skin cancer risk). Cervical cytology more frequent. Lymph nodes — monitor for lymphoproliferative disease.
Infections?
Cotrimoxazole prophylaxis for PCP first 6-12 months post-transplant. CMV monitoring. TB screening before starting. Ongoing infection vigilance — fever needs prompt assessment.
Sun protection?
Daily broad-spectrum SPF 50+ from the day of transplant onwards. Annual dermatology review. Skin cancer is the most common post-transplant malignancy.
What if I miss a dose?
Take when you remember if same day; if >12 hours late, skip and resume next dose. Do not double up. Consistent levels matter — discuss adherence with your transplant team.
Stopping?
Never stop without specialist guidance — risks acute rejection (transplant) or disease flare (autoimmune). Tapers happen over months, not days, and only when clinically appropriate.
Other Immunosuppressant & Cancer Medications
- Mycept — mycophenolate mofetil 250 mg — alternative MMF brand
- Mycofit — mycophenolate mofetil 500 mg
- Cyclophil ME — cyclosporine ME 25/50/100 mg
- Renodapt S — mycophenolate sodium 360 mg — enteric-coated
- Rapact — sirolimus 5/10 mg — mTOR inhibitor
More options in Anti Cancer Medication
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 250 mg |
|---|---|
| Quantity | 30 Capsule/s, 60 Capsule/s, 90 Capsule/s |
| Pharma Form | Capsule/s |
| Manufacturer | Panacea Biotech |
| Treatment | Anti Cancer |
| Generic Brand | Mycophenolate Mofetil |
Mycept
Q & A
Mycept
Related products
Reviews
There are no reviews yet